| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Buprenorphine/Naloxone |
| Brand | Suboxone® |
| Indication | Management of opiate addiction |
| Assessment Process | |
| Full submission received from Applicant | 02/01/2014 |
| NCPE assessment completed | 22/05/2014 |
| NCPE assessment outcome | Reimbursement Not Recommended |
Pharmacoeconomic Evaluation completed in November 2007. Suboxone cannot be considered a cost effective option for patients attending HSE clinics or in the community setting in Ireland.
Pharmacoeconomic Reassessment completed in 2014. The NCPE does not consider Suboxone® to be cost-effective compared to methadone for the treatment of opioid dependence.